Global Human Milk Oligosaccharides - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Human milk oligosaccharides market size in 2026 is estimated at USD 338.93 million, growing from 2025 value of USD 295.18 million with 2031 projections showing USD 676.17 million, growing at 14.82% CAGR over 2026-2031. This report is Segmented by Product Type (Fucosylated Neutral HMOs, Neutral Core HMOs, and Sialylated HMOs), by Form (Powder, Liquid, and Others) by Application (Food and Beverage, Dietary Supplements, Infant Formula, and Pharmaceuticals) and by Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Human Milk Oligosaccharides Market Trends and Insights

Rising Demand for Infant Formula Mimicking Human Breast Milk

One of the strongest forces driving the human milk oligosaccharides (HMO) market is the intensifying global focus on replicating the composition and health benefits of human breast milk in infant formula. Modern parents are more informed and discerning than ever, actively seeking nutritional solutions that provide immune, digestive, and cognitive advantages closely aligned with natural breastfeeding. Healthcare professionals likewise emphasize early-life nutrition that supports microbiome development and long-term resilience, fueling a shift toward advanced functional formulations. This momentum is reinforced by regulatory developments that legitimize and encourage the inclusion of HMOs; notably, the Food and Drug Administration (FDA)'s 2025 nutrient requirements review has explicitly called for evidence on the benefits of oligosaccharides for infant growth and health, signaling heightened institutional support for these bioactive compounds. As a result, manufacturers are accelerating research into multi-HMO blends and tailoring formulations to specific health outcomes, from gut barrier function to infection resistance.

Expansion of Premium Infant Nutrition Segment

As demand for premium infant nutrition surges, the human milk oligosaccharides (HMO) market is experiencing significant growth. Parents are increasingly opting for infant formulas enriched with bioactive ingredients, striving to emulate the functional properties of breast milk. This trend is propelled by a rising middle class in emerging markets and a heightened parental emphasis on products that enhance immunity, gut health, and cognitive development. With the market shifting its focus from basic nutrition to functional health benefits, HMOs have become key differentiators for infant formula brands. Vinamilk's introduction of Vietnam's first 6-HMO formula highlights its global aspiration. Manufacturers are now developing sophisticated formulations that closely resemble breast milk. By placing these HMO-rich formulas in their premium tiers, companies are capitalizing on the purchasing power of the growing middle class. In February 2025, a2 Milk launched its a2 Genesis infant formula, specifically designed for the Chinese market. This premium product features a 3-HMO blend (2′-FL, 3′-SL, and 6′-SL), combined with algal DHA, prebiotic GOS, and Bifidobacterium lactis HN019. This move underscores manufacturers' premium positioning strategy and their dedication to meeting the refined demands of parents seeking breast-milk-like advantages for their children.

Stringent Regulatory Hurdles in Emerging Markets

Stringent regulatory requirements in emerging markets restrict the growth of the human milk oligosaccharides (HMO) market. While scientific evidence supports the health benefits of HMOs, complex approval processes and diverse local standards in developing economies slow their market adoption. This contrasts with established markets like the Europe and United States, where multiple HMO structures have received novel food ingredient approval or GRAS (Generally Recognized As Safe) status. The absence of standardized regulatory frameworks for synthetic or biofermented HMOs in emerging markets extends product registration timelines. Health authorities often require extensive clinical data specific to regional populations to validate safety and efficacy. For manufacturers, these fragmented approval processes increase compliance costs and delay market entry, affecting investment returns in these regions. Additional challenges arise from changing national infant nutrition guidelines and labeling requirements, necessitating product reformulations and relabeling to maintain compliance. These regulatory barriers slow the introduction of HMO-enriched formulas in emerging markets, reducing access to advanced nutritional products and delaying the health benefits of HMOs for these populations.

Other drivers and restraints analyzed in the detailed report include:

• Growing Demand for Clean-Label, Natural, and Non-GMO Ingredients
• Consumer Preference for Functional, Science-Backed Ingredients
• Complex Manufacturing Process Requiring Biotech Expertise

Segment Analysis

In 2025, fucosylated neutral HMOs command a dominant 43.05% market share, largely due to the regulatory green light and expansive manufacturing capabilities of 2'-Fucosyllactose in key markets. This leadership is a testament to early commercialization triumphs and efficient production techniques, allowing competitive pricing for mainstream infant formulas. Neutral Core HMOs, which include Lacto-N-tetraose and Lacto-N-neotetraose, find themselves in a pivotal growth phase, buoyed by regulatory nods and their integration into multi-HMO blends. This shift underscores manufacturers' strategic pivot from singular components to intricate blends, mirroring the diverse oligosaccharide profile of breast milk.

Sialylated HMOs are rising, boasting a robust 16.05% CAGR projected through 2031. Their ascent is fueled by clinical findings linking them to cognitive benefits and a premium market stance appealing to health-focused consumers. With players like Kyowa Hakko Bio making waves with a 2023 launch, the market is witnessing a surge in investments towards fermentation platforms. These platforms, adept at churning out multiple HMO variants, are seen as key to seizing premium market slots and adapting to shifting consumer preferences. Notably, HMOs such as 3'-Sialyllactose and 6'-Sialyllactose, while offering cognitive benefits, come with a premium price tag, a reflection of their intricate manufacturing process and a scarcity of suppliers.

Complete Report Scope:

• By Product Type
  • Fucosylated Neutral HMOs
    • 2’-Fucosyllactose (2’-FL)
    • 3-Fucosyllactose (3’-FL)
    • Difucosyllactose (DFL)
  • Neutral Core HMOs
    • Lacto-N-tetraose (LNT)
    • Lacto-N-neotetraose (LNnT)
  • Sialylated HMOs
    • 3’-Sialyllactose (3’-SL)
    • 6’-Sialyllactose (6’-SL)
• By Form
  • Powder
  • Liquid
  • Others
• By Application
  • Food and Beverage
  • Dietary Supplements
  • Infant Formula
  • Pharmaceuticals
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Netherlands
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East and Africa

Geography Analysis

Asia-Pacific dominates with 45.22% market share in 2025 while simultaneously exhibiting the fastest regional growth at 15.98% CAGR through 2031, propelled by China's regulatory approvals, premium infant formula adoption, and manufacturing capacity expansion initiatives. The regional leadership reflects demographic advantages, including large birth cohorts, rising disposable incomes, and cultural emphasis on infant nutrition quality that drives premium product adoption. China's approval of 4 HMO types in 2024 catalyzed market expansion, while Vietnam's introduction of 6-HMO formulas by Vinamilk demonstrates regional innovation leadership. Additionally, regional strategies are evolving beyond regulatory compliance and manufacturing footprints to include targeted consumer education and healthcare professional engagement, which are crucial in accelerating HMO adoption.

North America maintains a significant market presence driven by established regulatory frameworks, with the Food and Drug Administration (FDA) Generally Recognized as Safe (GRAS) approvals enabling rapid product launches and consumer acceptance of functional ingredients in infant nutrition. The region benefits from advanced research infrastructure and clinical validation capabilities that support HMO development and commercialization. Europe represents a mature market with sophisticated regulatory requirements through European Food Safety Authority (EFSA) novel food approvals, while demonstrating steady growth driven by premium infant nutrition trends and clean-label consumer preferences.

Emerging regions, including South America, the Middle East, and Africa, present long-term growth opportunities as regulatory frameworks develop and economic conditions support premium infant nutrition adoption, though current market penetration remains limited by approval timelines and distribution infrastructure constraints. This blend of market education, strategic partnerships, and portfolio diversification across regions is expected to further solidify HMOs as a cornerstone of both pediatric and broader functional nutrition markets worldwide.

List of Companies Covered in this Report:

• BASF SE
• Abbott Laboratories
• Nestle SA
• Novonesis (Novozymes A/S)
• DSM-Firmenich (incl. Glycom A/S)
• International Flavors and Fragrances Inc. (IFF) (DuPont)
• Elicityl SA
• Medolac Laboratories
• Royal FrieslandCampina N.V.
• ZuChem Inc.
• Inbiose NV
• Glycosyn LLC
• Kyowa Hakko Bio Co. (Kirin Holdings)
• Chr. Hansen A/S
• Conagen, Inc.
• Arla Foods amba
• Dextra Laboratories Ltd
• Jennewein Biotechnologie GmbH
• BENEO
• GeneChem Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support